CanBas (4575) Stock Overview

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

4575 Stock Information

Symbol

4575

Address

2-2-1, OtemachiNumazu, 410-0801Japan

Founded

Trading hours

Website

https://www.canbas.co.jp

Country

🇯🇵 Japan

Phone Number

81 55 954 3666

CanBas (4575) Price Chart

CanBas Overview: Key Details and Summary

Stock data	2023	Change
Price	$9.54	N/A
Market Cap	$142.95M	N/A
Shares Outstanding	14.98M	54.67%
Employees	12.00	N/A
Shareholder Equity	1.93B	670.74%

Valuation	2023	Change
P/E Ratio	-0.11	N/A
P/B Ratio	0.07	N/A

Growth	2023	Change
Return on Equity	-0.0045	N/A

Earnings	2023	Change
Revenue	$0	N/A
Earnings	-$8.72M	N/A
EPS	-83.03	N/A
Earnings Yield	-8.70	N/A

Financial Strength	2023	Change
Total Assets	$14.62M	N/A
Cash on Hand	$11.34M	N/A
Debt to Equity	0.0006	-96.30%
Current Ratio	$13.44	205.92%